Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial

Background and Purpose: Laboratory experiments suggest statins reduce stroke severity and improve outcomes. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial was a placebo-controlled, randomized trial designed to determine whether treatment with atorvastatin reduces...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Goldstein, Larry B. (VerfasserIn) , Amarenco, Pierre (VerfasserIn) , Zivin, Justin (VerfasserIn) , Messig, Michael (VerfasserIn) , Altafullah, Irfan (VerfasserIn) , Callahan, Alfred (VerfasserIn) , Hennerici, Michael G. (VerfasserIn) , MacLeod, Mary J. (VerfasserIn) , Sillesen, Henrik (VerfasserIn) , Zweifler, Richard (VerfasserIn) , Michael, K. (VerfasserIn) , Welch, A. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: [1 November 2009]
In: Stroke
Year: 2009, Jahrgang: 40, Heft: 11, Pages: 3526-3531
ISSN:1524-4628
DOI:10.1161/STROKEAHA.109.557330
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/STROKEAHA.109.557330
Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/STROKEAHA.109.557330
Volltext
Verfasserangaben:Larry B. Goldstein, MD, Pierre Amarenco, MD, Justin Zivin, MD, PhD, Michael Messig, PhD, Irfan Altafullah, MD, Alfred Callahan, MD, Michael Hennerici, MD, PhD, Mary J. MacLeod, PhD, MBChB, Henrik Sillesen, MD, DMSc, Richard Zweifler, MD, K. Michael, and A. Welch, MB, ChB

MARC

LEADER 00000caa a2200000 c 4500
001 1751579263
003 DE-627
005 20220819135720.0
007 cr uuu---uuuuu
008 210317s2009 xx |||||o 00| ||eng c
024 7 |a 10.1161/STROKEAHA.109.557330  |2 doi 
035 |a (DE-627)1751579263 
035 |a (DE-599)KXP1751579263 
035 |a (OCoLC)1341398952 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Goldstein, Larry B.  |e VerfasserIn  |0 (DE-588)1229517316  |0 (DE-627)1751579549  |4 aut 
245 1 0 |a Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial  |c Larry B. Goldstein, MD, Pierre Amarenco, MD, Justin Zivin, MD, PhD, Michael Messig, PhD, Irfan Altafullah, MD, Alfred Callahan, MD, Michael Hennerici, MD, PhD, Mary J. MacLeod, PhD, MBChB, Henrik Sillesen, MD, DMSc, Richard Zweifler, MD, K. Michael, and A. Welch, MB, ChB 
264 1 |c [1 November 2009] 
300 |b Diagramme 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 17.03.2021 
520 |a Background and Purpose: Laboratory experiments suggest statins reduce stroke severity and improve outcomes. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial was a placebo-controlled, randomized trial designed to determine whether treatment with atorvastatin reduces strokes in subjects with recent stroke or transient ischemic attack (n=4731). We analyzed SPARCL trial data to determine whether treatment favorably shifts the distribution of severities of ischemic cerebrovascular outcomes.Methods— Severity was assessed with the National Institutes of Health Stroke Scale, Barthel Index, and modified Rankin Scale score at enrollment (1 to 6 months after the index event) and 90 days poststroke in subjects having a stroke during the trial.Results— Over 4.9 years, strokes occurred in 576 subjects. There were reductions in fatal, severe (modified Rankin Scale score 5 or 4), moderate (modified Rankin Scale score 3 or 2), and mild (modified Rankin Scale score 1 or 0) outcome ischemic strokes and transient ischemic attacks and an increase in the proportion of event-free subjects randomized to atorvastatin (P<0.001 unadjusted and adjusted). Results were similar for all outcome events (ischemic and hemorrhagic, P<0.001 unadjusted and adjusted) with no effect on outcome hemorrhagic stroke severity (P=0.174 unadjusted, P=0.218 adjusted). If the analysis is restricted to those having an outcome ischemic stroke (ie, excluding those having a transient ischemic attack or no event), there was only a trend toward lesser severity with treatment based on the modified Rankin Scale score (P=0.0647) with no difference based on the National Institutes of Health Stroke Scale or Barthel Index.Conclusion— The present exploratory analysis suggests that the outcome of recurrent ischemic cerebrovascular events might be improved among statin users as compared with nonusers. 
700 1 |a Amarenco, Pierre  |e VerfasserIn  |4 aut 
700 1 |a Zivin, Justin  |e VerfasserIn  |4 aut 
700 1 |a Messig, Michael  |e VerfasserIn  |4 aut 
700 1 |a Altafullah, Irfan  |e VerfasserIn  |4 aut 
700 1 |a Callahan, Alfred  |e VerfasserIn  |4 aut 
700 1 |a Hennerici, Michael G.  |d 1948-  |e VerfasserIn  |0 (DE-588)11587545X  |0 (DE-627)077527704  |0 (DE-576)290126444  |4 aut 
700 1 |a MacLeod, Mary J.  |e VerfasserIn  |4 aut 
700 1 |a Sillesen, Henrik  |e VerfasserIn  |4 aut 
700 1 |a Zweifler, Richard  |e VerfasserIn  |4 aut 
700 1 |a Michael, K.  |e VerfasserIn  |4 aut 
700 1 |a Welch, A.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Stroke  |d New York, NY : Association, 1970  |g 40(2009), 11, Seite 3526-3531  |h Online-Ressource  |w (DE-627)266879985  |w (DE-600)1467823-8  |w (DE-576)075145731  |x 1524-4628  |7 nnas  |a Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial 
773 1 8 |g volume:40  |g year:2009  |g number:11  |g pages:3526-3531  |g extent:6  |a Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial 
856 4 0 |u https://doi.org/10.1161/STROKEAHA.109.557330  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.ahajournals.org/doi/10.1161/STROKEAHA.109.557330  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210317 
993 |a Article 
994 |a 2009 
998 |g 11587545X  |a Hennerici, Michael G.  |m 11587545X:Hennerici, Michael G.  |d 60000  |d 62700  |e 60000PH11587545X  |e 62700PH11587545X  |k 0/60000/  |k 1/60000/62700/  |p 7 
999 |a KXP-PPN1751579263  |e 3889981593 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"family":"Goldstein","given":"Larry B.","roleDisplay":"VerfasserIn","display":"Goldstein, Larry B.","role":"aut"},{"family":"Amarenco","given":"Pierre","roleDisplay":"VerfasserIn","display":"Amarenco, Pierre","role":"aut"},{"role":"aut","display":"Zivin, Justin","roleDisplay":"VerfasserIn","given":"Justin","family":"Zivin"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Messig, Michael","given":"Michael","family":"Messig"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Altafullah, Irfan","given":"Irfan","family":"Altafullah"},{"given":"Alfred","family":"Callahan","role":"aut","display":"Callahan, Alfred","roleDisplay":"VerfasserIn"},{"display":"Hennerici, Michael G.","roleDisplay":"VerfasserIn","role":"aut","family":"Hennerici","given":"Michael G."},{"family":"MacLeod","given":"Mary J.","display":"MacLeod, Mary J.","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Henrik","family":"Sillesen","role":"aut","roleDisplay":"VerfasserIn","display":"Sillesen, Henrik"},{"given":"Richard","family":"Zweifler","role":"aut","display":"Zweifler, Richard","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Michael, K.","given":"K.","family":"Michael"},{"role":"aut","display":"Welch, A.","roleDisplay":"VerfasserIn","given":"A.","family":"Welch"}],"title":[{"title":"Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial","title_sort":"Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 17.03.2021"],"language":["eng"],"recId":"1751579263","name":{"displayForm":["Larry B. Goldstein, MD, Pierre Amarenco, MD, Justin Zivin, MD, PhD, Michael Messig, PhD, Irfan Altafullah, MD, Alfred Callahan, MD, Michael Hennerici, MD, PhD, Mary J. MacLeod, PhD, MBChB, Henrik Sillesen, MD, DMSc, Richard Zweifler, MD, K. Michael, and A. Welch, MB, ChB"]},"origin":[{"dateIssuedDisp":"[1 November 2009]","dateIssuedKey":"2009"}],"id":{"doi":["10.1161/STROKEAHA.109.557330"],"eki":["1751579263"]},"physDesc":[{"extent":"6 S.","noteIll":"Diagramme"}],"relHost":[{"recId":"266879985","language":["eng"],"corporate":[{"role":"isb","display":"American Heart Association","roleDisplay":"Herausgebendes Organ"}],"note":["Gesehen am 29.06.04"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Statin treatment and stroke outcome in the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trialStroke","part":{"year":"2009","issue":"11","pages":"3526-3531","text":"40(2009), 11, Seite 3526-3531","volume":"40","extent":"6"},"pubHistory":["1.1970 -"],"title":[{"title_sort":"Stroke","subtitle":"journal of the American Heart Association","title":"Stroke"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["1467823-8"],"eki":["266879985"],"issn":["1524-4628"]},"origin":[{"publisherPlace":"New York, NY ; Philadelphia, Pa.","publisher":"Association ; Lippincott Williams & Wilkins","dateIssuedKey":"1970","dateIssuedDisp":"1970-"}]}]} 
SRT |a GOLDSTEINLSTATINTREA1200